GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2011

Valeant to Buy Generics and OTC Drugs Firm PharmaSwiss for €350M

  • Valeant Pharmaceuticals is to acquire Switzerland-based generics and OTC drug firm PharmaSwiss for €350 million (about $475 million). Some of the latter’s shareholders could receive up to another €30 million (nearly $41 million) dependent on the achievement of certain milestones.

    PharmaSwiss is focused on products in the therapeutic areas of heart and circulatory diseases, pain management, anti-infectives, rheumatic diseases, neurological and psychiatric conditions, oncology, and gastroenterology. It has operations in 19 countries throughout Central and Eastern Europe as well as Greece and Israel. The firm also has established partnerships with pharma and biotech companies, through which it provides expertise in fields spanning regulation compliance, sales, marketing, and distribution.

    It recorded revenues of approximately €180 million in 2010 (about $245 million) and has witnessed revenue growth of about 20% per year over the last five years. Sales for 2011 are expected to exceed €200 million (roughly $272 million). PharmaSwiss has about €38 million (about $52 million) in cash on hand and carries no debt.

    Once the acquisition has been completed, PharmaSwiss’ senior management team will remain with Valeant, and it is expected that at some future point the Valeant business in Central Europe will be combined under the PharmaSwiss corporate structure, which is based in Zug, Switzerland.

    Valeant maintains acquiring PharmaSwiss will solidify its positon in Central and Eastern Europe and provides an attractive partnering strategy as well as complementary branded generics and OTC products to help strengthen its presence in the region.

    “Valeant’s additional resources, professional approach, focused pipeline, and strong commitment to supporting all three legs of the PharmaSwiss business model—representation of multinationals, licensing from specialty pharma, and own brands—will enable us to build on our winning strategy of serving partners,” adds Pavel Mirovsky, Ph.D., PharmaSwiss CEO. “Valeant Europe’s strong presence in Poland, the region’s largest market, fills an important gap and should contribute to transaction synergies.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?